

Fellow Publications/Presentations January through December 2022

Publications

1. **Barot SV**, Roesch E, Abraham J. Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer. *Expert Rev Anticancer Ther.* 2022 Dec;22(12):1289-1299. doi: 10.1080/14737140.2022.2146580. Epub 2022 Nov 17. PMID: 36373394.
2. **Cortese MJ**, Sauter C. A "CRISPR" non-viral manufacturing approach for CAR T cell therapies. *Mol Ther.* 2022 Nov 2;30(11):3338-3340. doi: 10.1016/j.ymthe.2022.09.022. Epub 2022 Oct 20. PMID: 36265492; PMCID: PMC9637580.
3. **Cortese MJ**, Wei W, Cerdeña S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, Portell C, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. *Leuk Lymphoma.* 2023 Jan;64(1):107-118. doi: 10.1080/10428194.2022.2140281. Epub 2022 Nov 2. PMID: 36323309.
4. Koenig KL, **Curley TP**, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. *Hematol Oncol.* 2022 Feb;40(1):115-118. doi: 10.1002/hon.2941. Epub 2021 Nov 2. PMID: 34713477.
5. **Dima D**, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Multiple Myeloma Therapy: Emerging Trends and Challenges. *Cancers (Basel).* 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082. PMID: 36077618; PMCID: PMC9454959.
6. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilan MA, Caimi PF, Choueiri TK, **Dawsey SJ**, et. al. COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. *JAMA Netw Open.* 2022 Jan 4;5(1):e2142046. doi: 10.1001/jamanetworkopen.2021.42046. Erratum in: *JAMA Netw Open.* 2022 May 2;5(5):e2217965. PMID: 34982158; PMCID: PMC8728628.
7. Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, **Dawsey S**, et. al. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. *Clin Genitourin Cancer.* 2022 Oct;20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001. Epub 2022 Jun 5. PMID: 35778337.
8. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, **Dawsey S**, et. al. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. *Clin Genitourin Cancer.* 2022 Dec;20(6):558-567. doi: 10.1016/j.clgc.2022.08.006. Epub 2022 Aug 19. PMID: 36155169.

9. Cherico AS, Rizvi A, **Jayakrishnan T**, Mewawalla P. Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment. *BMJ Case Rep.* 2022 Jul 11;15(7):e249737. doi: 10.1136/bcr-2022-249737. PMID: 35817492; PMCID: PMC9274533.
10. **Hubben A**, McCrae KR. Emerging Therapies in Antiphospholipid Syndrome. *Transfus Med Rev.* 2022 Oct;36(4):195-203. doi: 10.1016/j.tmr.2022.09.002. Epub 2022 Sep 24. PMID: 36272841.
11. **Lemmon CA**, Zabor EC, Pennell NA. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. *Oncologist.* 2022 May 6;27(5):407-413. doi: 10.1093/oncolo/oyac021. PMID: 35285487; PMCID: PMC9074960.
12. **Lemmon CA**, Videtic GMM, Murthy S, Stephans KL, Shapiro M, Ahmad U, Raymond D, Velcheti V, Bribriescu A, Jia X, Stevenson J, Pennell NA. A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC. *JTO Clin Res Rep.* 2022 Jun 15;3(7):100359. doi: 10.1016/j.jtocrr.2022.100359. PMID: 35815318; PMCID: PMC9257414.
13. **Muthusamy B**, Patil PD, Pennell NA. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer. *J Natl Compr Canc Netw.* 2022 Aug;20(8):953-961. doi: 10.6004/jnccn.2022.7021. PMID: 35948038.
14. Catania C, **Muthusamy B**, Spitaleri G, Del Signore E, Pennell NA. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. *Clin Lung Cancer.* 2022 Mar;23(2):108-115. doi: 10.1016/j.clc.2021.11.003. Epub 2021 Nov 11. PMID: 34952792.
15. **Muthusamy B**, Pennell N. Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. *J Thorac Oncol.* 2022 Feb;17(2):179-181. doi: 10.1016/j.jtho.2021.11.012. PMID: 35074223.
16. **Nguyen MT**, Wei W, Cooper G, Khorana AA, Kamath S. (2023) Shorter Time to Treatment is Associated with Improved Survival in Rural Patients with Breast Cancer Despite Other Adverse Socioeconomic Factors. *Oncology.* 37(1):19-24. PMID: 36724138
17. Fu J, Reid SA, French B...COVID-19 and Cancer Consortium [including **Nizam A**]. Racial Disparities in COVID-19 Outcomes Among Black and White Patients with Cancer. *JAMA Netw Open.* 2022;5(3):e224304. **PMID: 35344045**
18. Rubinstein SM, Bhutani D, Lynch RC, et al [including **Nizam A**]. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis. *Blood Cancer Discov.* 2022. Online ahead of print. **PMID: 35262738**
19. Elkrief A, Hennessy C, Kuderer NM, et al [including **Nizam A**]. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. *Lancet Healthy Longev.* 2022;3(3):e143-e152. **PMID: 35187516**

20. Hawley JE, Sun T, Chism DD...COVID-19 and Cancer Consortium [including **Nizam A**]. Assessment of Regional Variability in COVID-19 Outcomes Among Patients with Cancer in the United States. *JAMA Netw Open*. 2022;5(1):e2142046. **PMID: 34982158**
21. Koshkin VS, Henderson N, James M, et al [including **Nizam A**]. Efficacy of enfortumab vedotin in metastatic urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. *Cancer*. 2022;128(6):1194-1205. **PMID: 34882781**
22. Oesterreich S, Nasrazadani A, Zou J, Carleton N, **Onger T**, et. al. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. *J Natl Cancer Inst*. 2022 Nov 14;114(11):1511-1522. doi: 10.1093/jnci/djac157. PMID: 36239760; PMCID: PMC9664185.
23. **Roof L**, Wei W, Tullio K, Pennell NA, Stevenson JP. Impact of Socioeconomic Factors on Overall Survival in SCLC. *JTO Clin Res Rep*. 2022 Jun 18;3(7):100360. doi: 10.1016/j.jtocrr.2022.100360. PMID: 35815321; PMCID: PMC9257417.
24. **Trunk AD**, Shewan SK, Lee CJ, Parker CJ, Couriel DR. Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination. *Bone Marrow Transplant*. 2022 Mar;57(3):502-503. doi: 10.1038/s41409-021-01543-z. Epub 2022 Jan 11. PMID: 35017662; PMCID: PMC8751659.
25. **Trunk A**, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. *J Natl Compr Canc Netw*. 2022 Feb;20(2):144-150. doi: 10.6004/jnccn.2021.7059. PMID: 35130499.
26. Nevala-Plagemann C, Iyengar S, **Trunk AD**, Pappas L, Haaland B, Garrido-Laguna I. Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. *J Natl Compr Canc Netw*. 2022 Feb 4;20(3):268-275. doi: 10.6004/jnccn.2021.7079. PMID: 35120306.
27. Varma R, **Wright M**, Abraham J, Kruse M. Immune checkpoint inhibition in early-stage triple-negative breast cancer. *Expert Rev Anticancer Ther*. 2022 Nov;22(11):1225-1238. doi: 10.1080/14737140.2022.2139240. Epub 2022 Nov 14. PMID: 36278877.

Poster Presentations/Abstracts

1. Buchalter R, Schmit S, **Barot SV**, Liska D, Khorana AA. Hot and cold spots of young-onset colorectal cancer mortality in U.S. counties, 1999-2019. American Association for Cancer Research Annual Meeting. New Orleans, LA, April 2022 (Poster)
2. **Barot SV**, Sangwan N, Nair KG, Schmit S, Xiang S, Kamath SD, Liska D, Khorana AA. Tumor microbiome variation in young versus average onset colorectal cancer. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 2022 (Poster)
3. Deshpande S, Wei W, Tullio K, **Barot SV**, Nair KG, et. al. Comparison of comprehensive genomic profiles between young-onset and average-onset colorectal cancer. American

Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 2022 (Poster)

4. **Delasos L**, et. al. Texture-based CT radiomics distinguishes radiation and immunotherapy induced pneumonitis in stage III NSCLC. ASCO Annual Meeting. Chicago, IL. June 2022 (Poster)
5. **Dima D**, Ullah F, Omar N, et. al. Clinical and Mechanistic Relationship of TCell Large Granular Lymphocytic Leukemia (TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS). ASH Annual Meeting. New Orleans, LA. December 2022 (Poster)
6. **Dima D**, Hasipek M, Singh D, et. al. Heightened Endoplasmic-Reticulum Stress is a targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma. ASH Annual Meeting. New Orleans, LA. December 2022 (Poster)
7. **Jayakrishnan TJ**, et. al. Comparison of characteristics and outcomes of young onset versus average onset pancreatobiliary adenocarcinoma. ASCO Annual Meeting. Chicago, IL. June 2022 (Poster)
8. **Jayakrishnan TJ**, et. al. Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma. 2023 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA. January 2023 (Poster)
9. **Lopetegui-Lia N**, et. al. Immunotherapy Response in Cutaneous Squamous Cell Carcinoma Patients with Cranial Nerve Involvement. 2022 Multidisciplinary Head and Neck Cancers Symposium. Phoenix, AZ. February 2022 (Poster)
10. **Lopetegui-Lia N**, et. al. The impact of Sociodemographic Disparities on Overall Survival of Adolescent and Young Adults (AYA) with Invasive Breast Cancer. San Antonio Breast Cancer Symposium. San Antonio, TX. December 2022 (Poster)
11. **Nizam A**, Tzeng A, Wei W, Rayman PA, Pavicic PG, Makarov V, Juric I, Alban T, Swaidani S, Sheng IY, Gilligan TD, Gupta S, Diaz-Montero CM, Ornstein MC. Immunological correlates of response and immune-mediated toxicity in checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts). Poster presentation at ASCO Genitourinary Cancers Symposium; February 18, 2022; San Francisco, CA. (Poster)
12. **Nguyen, MT.**, Krach J., Knight J., Thompson C. Perceived Risk of Breast Cancer and God Health Locus of Control in high Risk White and African American Women. ASCO Annual Meeting. Chicago, IL. June 2022 (Poster)
13. Hurwitz H, Combs P, Ribbins M, **Nguyen MT.** et. al. Faith-Based Communities' Preferred Interventions to Improve Black/African-American Persons Participation in Medical Research and Clinical Trials, A Focus Group Study. ASCO Annual Meeting, 2023
14. **Roof L**, et. al. Positive Impact of Academic Center Care on Overall Survival in Malignant Pleural Mesothelioma (MPM): A National Cancer Database (NCDB) Socioeconomic Factor Analysis. ASCO Annual Meeting. Chicago, IL. June 2022 (Poster)

15. **Roof L**, Wei W, Stevenson J. Patient Demographic and Socioeconomic Differences in Non-Small Cell and Small Cell Lung Cancers: Impact on Outcomes. NCCN 2022 Annual Conference. Orlando, FL. March 2022. (Poster)
16. **Roof L**, et. al. Patterns and Outcomes of Palliative Radiation Therapy with Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. SITC's 37th Annual Meeting. Boston, MA. November 2022 (Poster)
17. **Schuster J**, et. al. Risk of Thromboembolism in Patients Receiving Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma. International Kidney Cancer Symposium. Austin, TX. November 2022 (Poster)
18. **Shah H**, O'Conke D, Zhao R, et. al. Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers. ASH Annual Meeting. New Orleans, LA. December 2022 (Poster)
19. **Trunk AD**, Brunstein C. Does use of *ex vivo* expanded cord blood lead to improved outcomes compared to unmanipulated umbilical cord blood or haploidentical graft in myeloablative hematopoietic cell transplant? ASTCT/CIBMTR Tandem Meeting. Orlando, FL. February 2022 (Committee Presentation)